SALT LAKE
CITY, Feb. 1, 2024 /PRNewswire/ --
Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"),
a molecular diagnostics company with a unique, patented platform
for the development of molecular diagnostic tests, announced today
the list of events it has chosen to exhibit at or participate in
during February, 2024, and which strategically align with the
Company's vision.
At each event, Co-Dx will discuss its upcoming
at-home and point-of-care Co-Dx™ PCR platform technology*, which
has been designed to bring PCR diagnostics to the point-of-care in
the service of achieving the Company's mission of increasing
accessibility of affordable gold-standard PCR diagnostics around
the world.
- Advanced TB Diagnostics workshop in Chennai, India; January
29-February 2, 2024: A capacity-building workshop for
countries in the Southeast Asian region, the event is hosted by
ICMR-National Institute for Research in Tuberculosis (NIRT), in
association with McGill International TB Centre and other
collaborative partners. CoSara Diagnostics, the Company's joint
venture in India, has been invited
to give a brief presentation on the Co-Dx PCR Pro™ and upcoming
test for tuberculosis as an example of innovative new tools being
introduced to help battle TB. The presentation will take place on
Friday, February 2, 2024.
- Medlab Middle East in
Dubai; Feb. 5-8, 2024: The 23rd Medlab Middle
East meeting is expected to host over 30,000 visitors and more than
900 exhibitors from over 40 countries, catering to the global
medical laboratory community and showcasing the latest in
laboratory innovation and technology. The Middle East has represented an important
market for the Company's products, and the Company is currently in
the process of exploring a registration with the SFDA in
Saudi Arabia for the Co-Dx PCR Pro
and Co-Dx PCR COVID-19 Test kit. Co-Dx and CoSara representatives
will be in attendance at Booth Z3.B39 in the Dubai World Trade Centre.
- Life Sciences Day on the Hill, Salt
Lake City, UT; Feb. 7, 2024:
With more than $18B in GDP, +1,600
companies and over 40,000 jobs, Utah's life sciences industry is one of the
fastest growing in the nation. The annual Life Sciences Day on the
Hill is hosted by BioUtah in conjunction with the Governor's Office
of Economic Opportunity. This year, the event will feature displays
from over 20 local life science companies in the Utah State Capital
Rotunda from 11:00 am - 2:00 PM
MST.
- RSVVW in Mumbai, India;
Feb. 13-16, 2024: The 8th
Respiratory Syncytial Virus Foundation's (ReSViNET) RSVVW
conference, a global conference on novel RSV preventative and
therapeutic interventions, will be held this year in India, a country where the Company expects the
transformational nature of its upcoming platform to play a large
role in improving the availability of affordable gold-standard PCR
diagnostics, including its Flu A/B, COVID-19 and RSV multiplex test
currently in development. ReSViNET's collaborations with global
leaders, including WHO, Bill & Melinda Gates Foundation, ISIRV,
PATH, EMA, FDA and more make the conference an ideal setting for
Co-Dx and CoSara representatives to introduce the new platform in
the joint exhibit.
*The Co-Dx PCR platform (including the Co-Dx PCR Home™, Co-Dx
PCR Pro™, mobile app, and all associated test kits) is subject to
review by the FDA and/or other regulatory bodies and is not yet
available for sale. The PCR Pro and Co-Dx COVID-19 Test are
currently under review by the FDA.
About Co-Diagnostics,
Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics
company that develops, manufactures and markets state-of-the-art
diagnostics technologies. The Company's technologies are utilized
for tests that are designed using the detection and/or analysis of
nucleic acid molecules (DNA or RNA). The Company also uses its
proprietary technology to design specific tests for its Co-Dx PCR
at-home and point-of-care platform and to locate genetic markers
for use in applications other than infectious disease.
Forward-Looking Statements:
This press
release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
(PSLRA) that are subject to a number of risks and uncertainties.
Forward-looking statements can be identified by words such as
"believes," "expects," "estimates," "intends," "may," "plans,"
"will" and similar expressions, or the negative of these words.
Such forward-looking statements are based on facts and conditions
as they exist at the time such statements are made and predictions
as to future facts and conditions. Forward-looking statements in
this release may include statements regarding our belief that our
new platform will help support the Company's worldwide efforts to
help prevent the spread of infectious diseases and our belief that
our new platform has the potential to dramatically improve access
to diagnostics and reduce healthcare costs. Actual results may
differ materially from those contemplated or anticipated by such
forward-looking statements. Readers of this press release are
cautioned not to place undue reliance on any forward-looking
statements. There can be no assurance that any of the anticipated
results will occur on a timely basis or at all due to certain risks
and uncertainties, a discussion of which can be found in our Risk
Factors disclosure in our Annual Report on Form 10-K, filed with
the Securities and Exchange Commission (SEC) on March 16, 2023, and in our other filings with the
SEC. The Company does not undertake any obligation to update any
forward-looking statement relating to matters discussed in this
press release, except as may be required by applicable securities
laws.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/co-diagnostics-inc-shares-list-of-upcoming-industry-conferences-and-events-for-february-2024-302050509.html
SOURCE Co-Diagnostics